ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2235

Shocking? a Systematic Review of Adrenal Insufficiency in Adults on Oral Steroids

Rebecca M Joseph1, Louise Hunter2, David W. Ray2 and William G Dixon3, 1NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, 2Institute of Human Development, The University of Manchester, Manchester, United Kingdom, 3Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: glucocorticoids

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Epidemiology and Public Health Poster III (ACR): Gout and Non-Inflammatory Musculoskeletal Conditions

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: One percent of the adult population are, at any one time, prescribed oral glucocorticoids (GC). GCs are known to be associated with hypothalamic-pituitary-adrenal axis suppression. However, there remains uncertainty regarding: (1) the prevalence of GC-induced adrenal insufficiency (AI); (2) the effects of GC dose and duration; and (3) the time course of adrenal recovery and how GCs should be withdrawn. We undertook a systematic literature review to address these questions.

Methods: Searches were performed in MEDLINE and Web of Science in November 2014. Eligible papers studied adult patients with an indication for long-term GCs, exposure to oral GCs, and adrenal function tests. Screening was performed in duplicate and additional articles identified through citation screening. Three categories each for increasing dose, duration and cumulative dose were assessed.

Results: From 645 screened papers, 42 met the inclusion criteria (14 randomised controlled trials and 28 observational studies). The prevalence of AI ranged from 0-100%. When examined within exposure categories, the prevalence still ranged from 0-100%, with medians of 33-43%. Only exposure <5mg prednisolone equivalent dose/day had reduced AI (range 0-36%, median 15%). There was evidence of persisting adrenal suppression 1-3 years after GC cessation. Only 5 studies reported weaning of GCs and these were too heterogeneous in study design to draw useful conclusions.

Conclusion: Significant variation exists in the reported prevalence of AI after oral GC therapy, irrespective of exposure category. There is evidence, albeit limited, that even low doses can suppress adrenal function, and some patients may have AI after several years of cessation. We suggest clinicians be vigilant for AI with all doses and durations of oral GC therapy. The evidence base supporting current practice, particularly with regards to withdrawal of steroids, is scant. There is imperative need for large-scale prospective studies to guide future practice.


Disclosure: R. M. Joseph, None; L. Hunter, None; D. W. Ray, None; W. G. Dixon, None.

To cite this abstract in AMA style:

Joseph RM, Hunter L, Ray DW, Dixon WG. Shocking? a Systematic Review of Adrenal Insufficiency in Adults on Oral Steroids [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/shocking-a-systematic-review-of-adrenal-insufficiency-in-adults-on-oral-steroids/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/shocking-a-systematic-review-of-adrenal-insufficiency-in-adults-on-oral-steroids/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology